AstraZeneca Announces Two Key Appointments: New Head of US Biopharmaceuticals and Incoming Investor Relations Lead

On January 8, AstraZeneca announced two personnel changes. Rick R. Suarez has been appointed as the Head of the US Biopharmaceuticals Business Unit, taking full charge of AstraZeneca’s previously announced $50 billion investment plan for research, development, and manufacturing in the United States, includingVirginia builds a facility costing45billion-dollar production base, marking AstraZeneca's largest single production investment globallyThis plan supports AstraZeneca's goal of achieving $80 billion in total revenue by 2030, with half expected to come from the United States.

In addition, Joris Silon, the new Head of Investor Relations, will succeed Andy Barnett on March 1, 2026, based in Cambridge, UK. Joris will transition from his role as President of AstraZeneca US, where he led and drove significant growth for AstraZeneca in its largest market. With extensive pharmaceutical experience, Joris has held leadership positions across Asia, Europe, and the United States since joining AstraZeneca in 2000.

Public records indicate that Rick R. Suarez, who has recently assumed his new role, was born in the United States and joined AstraZeneca in 1999 as a pharmaceutical sales representative. He has held various functional positions across the business, including in marketing, medical affairs, and market access. In 2020, Mr. Suarez began serving as President of AstraZeneca Spain, where he led one of AstraZeneca’s best-performing European markets and expanded Spain’s role in global clinical development.